共 50 条
- [1] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance statusJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)Alessi, Joao, VRicciuti, BiagioJimenez-Aguilar, ElizabethHong, FangxinWei, ZihanNishino, MizukiPlodkowski, Andrew J.Sawan, PeterLuo, JiaRizyi, HiraCarter, Brett W.Heymach, John, VAltan, MehmetHellmann, MatthewAwad, Mark
- [2] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionANNALS OF ONCOLOGY, 2019, 30 (10) : 1653 - 1659Aguilar, E. J.Ricciuti, B.Gainor, J. F.Kehl, K. L.Kravets, S.Dahlberg, S.Nishino, M.Sholl, L. M.Adeni, A.Subegdjo, S.Khosrowjerdi, S.Peterson, R. M.Digumarthy, S.Liu, C.Sauter, J.Rizvi, H.Arbour, K. C.Carter, B. W.Heymach, J. V.Altan, M.Hellmann, M. D.Awad, M. M.
- [3] Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non-small cell lung cancer.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)De Castro Barrichello, Adriana PaulaAlessi, Joao Victor MachadoRicciuti, BiagioPecci, FedericaVaz, Victor R.Lamberti, GiuseppeTurner, Madison M.Pfaff, Kathleen L.Rodig, Scott J.Awad, Mark M.
- [4] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expressionCANCER SCIENCE, 2022, 113 (06) : 2109 - 2117Ikezawa, YasuyukiMizugaki, HidenoriMorita, RyoTateishi, KazunariYokoo, KeikiSumi, ToshiyukiKikuchi, HajimeKitamura, YasuoNakamura, AtsushiKobayashi, MakiAso, MariKimura, NozomuYoshiike, FumiakiFuruta, MegumiTanaka, HisashiSekikawa, MotokiHachiya, TsutomuNakamura, KeiichiShimokawa, MototsuguOizumi, Satoshi
- [5] First-line immunotherapy in PD-L1-high non-small cell lung cancer: indirect treatment comparison of pembrolizumab and atezolizumabONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 227 - 228Griesinger, F.Sibbe, M. S.Hieke-Schulz, S.Buhck, H.Reinmuth, N.Rittmeyer, A.
- [6] Effect of first-line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Veluswamy, RajwanthJi, JiayiHu, LiangyuanWang, XiaoliangSmith, Cardinale B.Kale, Minal
- [7] First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance statusEUROPEAN JOURNAL OF CANCER, 2020, 130 : 155 - 167Facchinetti, FrancescoMazzaschi, GiuliaBarbieri, FaustoPassiglia, FrancescoMazzoni, FrancescaBerardi, RossanaProto, ClaudiaCecere, Fabiana LetiziaPilotto, SaraScotti, VieriRossi, SabrinaDel Conte, AlessandroVita, EmanueleBennati, ChiaraArdizzoni, AndreaCerea, GiulioMigliorino, Maria RitaSala, ElisaCamerini, AndreaBearz, AlessandraDe Carlo, ElisaZanelli, FrancescaGuaitoli, GiorgiaGarassino, Marina ChiaraCiccone, Lucia PiaSartori, GiuliaToschi, LucaDall'Olio, Filippo GustavoLandi, LorenzaPizzutilo, Elio GregoryBartoli, GabrieleBaldessari, CinziaNovello, SilviaBria, EmilioCortinovis, Diego LuigiRossi, GiulioRossi, AntonioBanna, Giuseppe LuigiCamisa, RobertaDi Maio, MassimoTiseo, Marcello
- [8] Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Addeo, AlfredoMetro, GiulioSignorelli, DiegoEconomopoulou, PanagiotaRoila, FaustoBanna, Giuseppe LuigiDe Toma, AlessandroCamerini, AndreaChristopoulou, AthinaLo Russo, GiuseppeGaletta, DomenicoMunarriz, Beatriz JimenezCollazo, AnaCalles, AntonioBaxevanos, PanagiotisLinardou, HelenaKosmidis, Paris A.Mountzios, Giannis SocratesGarassino, Marina ChiaraFriedlaender, Alex
- [9] First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%FUTURE ONCOLOGY, 2021, 17 (23) : 3007 - 3016Descourt, RenaudChouaid, ChristosPerol, MauriceBesse, BenjaminGreillier, LaurentBylicki, OlivierRicordel, CharlesGuisier, FlorianGervais, RadjSchott, RolandAuliac, Jean-BernardRobinet, GillesDecroisette, Chantal
- [10] Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1THORACIC CANCER, 2022, 13 (11) : 1611 - 1618Masuda, TakeshiFujitaka, KazunoriSuzuki, TomokoHamai, KosukeMatsumoto, NaokoMatsumura, MiraiIsoyama, ShokoUeno, SayakaMito, MineyoYamaguchi, KakuhiroSakamoto, ShinjiroKawano, ReoMasuda, KenNishino, RyoheiIshikawa, NobuhisaYamasaki, MasahiroHattori, Noboru